Eton New Logo.jpg
Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
03 mai 2023 16h05 HE | Eton Pharmaceuticals
DEER PARK, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton New Logo.jpg
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
16 mars 2023 16h01 HE | Eton Pharmaceuticals
Q4 2022 revenue of $8.5 millionQ4 Product sales and royalty revenue up 220% from prior year and 9% from Q3Q4 positive net incomeManagement to hold conference call today at 4:30pm ET DEER PARK, Ill.,...
Eton New Logo.jpg
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
15 mars 2023 06h50 HE | Eton Pharmaceuticals
-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or...
Eton New Logo.jpg
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
07 mars 2023 16h05 HE | Eton Pharmaceuticals
DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton New Logo.jpg
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
11 janv. 2023 06h50 HE | Eton Pharmaceuticals
-- Product previously granted orphan drug designation for methanol poisoning ---- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton...
Eton New Logo.jpg
Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results
10 nov. 2022 16h05 HE | Eton Pharmaceuticals
Q3 2022 revenue of $3.2 million, product sales and royalty revenue up 315% from prior year and 37% from Q2 2022Strong sales growth of ALKINDI SPRINKLE® and Carglumic AcidThird commercial product,...
Eton New Logo.jpg
Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
02 nov. 2022 16h05 HE | Eton Pharmaceuticals
DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton New Logo.jpg
Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
18 oct. 2022 06h50 HE | Eton Pharmaceuticals
DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton New Logo.jpg
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
13 sept. 2022 09h00 HE | Eton Pharmaceuticals
-- Expected to be accretive to 2023 earnings -- DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical...
Eton New Logo.jpg
Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
30 août 2022 16h05 HE | Eton Pharmaceuticals
DEER PARK, Ill., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...